	US 11,925,642 B2
	Regulation of eIF4E activity for migraine therapy
Greg Dussor, Dallas, TX (US); and Jacob E. Lackovic, Dallas, TX (US)
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Oct. 7, 2021, as Appl. No. 17/495,902.
Claims priority of provisional application 63/089,326, filed on Oct. 8, 2020.
Prior Publication US 2022/0110937 A1, Apr. 14, 2022
Int. Cl. A61K 31/506 (2006.01); A61K 31/05 (2006.01); A61K 31/167 (2006.01); A61K 31/19 (2006.01); A61K 31/343 (2006.01); A61K 31/426 (2006.01)

CPC A61K 31/506 (2013.01) [A61K 31/05 (2013.01); A61K 31/167 (2013.01); A61K 31/19 (2013.01); A61K 31/343 (2013.01); A61K 31/426 (2013.01)]

19 Claims

1. A method of preventing, treating, or inhibiting migraine in a human subject, comprising administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine by:

suppressing or inhibiting translation of at least one eIF4E-dependent mRNA in the subject;

suppressing or inhibiting eIF4E activity in the subject;

suppressing or inhibiting phosphorylation of 4E-BP or Ser209 of eIF4E in the subject; and/or

suppressing or inhibiting MNK activity in the subject.